Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

NCT07432295 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Advanced Cancer
Metastatic Cancer
Gastric Cancer
Gastroesophageal Junction Carcinoma
Esophageal Adenocarcinoma

Interventions

DRUG: Givastomig
DRUG: Nivolumab
DRUG: 5Fluorouracil
DRUG: Leucovorin
DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

I-Mab Biopharma US Limited